SCHEMBL8607295

SCHEMBL8607295

O=C(O)c1ccc2nc(-c3nnn[nH]3)cn2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.50
KDM4E B2RXH2 9/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 1/20 0.50
HSP90AA1 P07900 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
RAB9A P51151 10/20 0.39
NPC1 O15118 9/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
POLB P06746 3/20 0.39
GAA P10253 2/20 0.39
ALDH1A3 P47895 2/20 0.38
GLA P06280 1/20 0.37
MAPT P10636 2/20 0.36
CDK5 Q00535 2/20 0.36
CHEK1 O14757 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8608866 0.82 SUV39H2 (0.38) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL8607791 0.80 APP (0.36) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL8607360 0.79 ALDH1A3 (0.45) ALDH1A1KDM4EKMT2AMEN1RAB9A
SCHEMBL8610050 0.78 TBXAS1 (0.42) SMN1; SMN2HSD17B10
SCHEMBL8606962 0.78 KDM6B (0.35) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL8608922 0.77 ALDH1A1 (0.33) ALDH1A1KDM4EKMT2AMEN1RAB9A
SCHEMBL8607307 0.76 APP (0.34) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL8606803 0.74 CPB2 (0.36) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL4726717 0.74 ALDH1A1 (0.68) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL8607617 0.74 KDM4E (0.36) KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0436831-A2 Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury G.D. Searle & Co. (US) 1991-07-17 EP claimed
WO-1991008211-A1 IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY G.D. SEARLE & CO. (US) 1991-06-13 WO claimed
US-5763597-A Orally active adenosine kinase inhibitors METABASIS THERAPEUTICS, INC. (US) 1998-06-09 US disclosed
US-5721356-A SUBSTITUTED 5-ARYLPYRROLO(2,3-D)PYRIMIDINE OR 3-ARYLPYRAZOLO(3,4-D)PYRIMIDINE; CARDIOVASCULAR DISORDERS, BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS GENSIA, INC. (US) 1998-02-24 US disclosed
EP-0436831-A2 Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury G.D. Searle & Co. (US) 1991-07-17 EP disclosed
WO-1991008211-A1 IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY G.D. SEARLE & CO. (US) 1991-06-13 WO disclosed